Literature DB >> 22073495

Approach to patients with eosinophilia.

Lanny J Rosenwasser1.   

Abstract

Eosinophilia is commonly seen in medical practice and can underlie a variety of medical conditions. Eosinophilia, defined as peripheral blood eosinophil counts greater than 500 per microliter, may vary from mild-severe. Idiopathic hypereosinophilic syndrome has been identified as an unusual cause of moderate to severe eosinophilia. Progress in treatment of this condition has accompanied greater understanding about the basic biology of eosinophils. This review will highlight the approach to patients with eosinophilia, along with associated conditions and syndromes.

Entities:  

Mesh:

Year:  2011        PMID: 22073495      PMCID: PMC6188379     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  10 in total

Review 1.  Practical approach to the patient with hypereosinophilia.

Authors:  Florence Roufosse; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2010-06-09       Impact factor: 10.793

2.  IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome.

Authors:  Lanny J Rosenwasser; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

Review 3.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

Review 4.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 5.  The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Authors:  M J Chusid; D C Dale; B C West; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

6.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

7.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

Review 8.  Eosinophilic disorders.

Authors:  Dagmar Simon; Hans-Uwe Simon
Journal:  J Allergy Clin Immunol       Date:  2007-04-02       Impact factor: 10.793

9.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Authors:  Princess U Ogbogu; Bruce S Bochner; Joseph H Butterfield; Gerald J Gleich; Johannes Huss-Marp; Jean Emmanuel Kahn; Kristin M Leiferman; Thomas B Nutman; Florian Pfab; Johannes Ring; Marc E Rothenberg; Florence Roufosse; Marie-Helene Sajous; Javed Sheikh; Dagmar Simon; Hans-Uwe Simon; Miguel L Stein; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

Review 10.  Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.

Authors:  Peter Valent
Journal:  Blood Rev       Date:  2009-02-25       Impact factor: 8.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.